mRNA-1010은 Moderna가 처음으로 임상 중인 계절성 인플루엔자 mRNA 백신 후보물질로, WHO가 인플루엔자 예방에 권장하는 4종의 인플루엔자(인플루엔자 A/H1N1, A/H3N2, A/H3N2, 인플루엔자 B/Yamagata- 및 B/Victoria-계통)의 헤마글루티닌 당단백질을 코딩하는 4가 백신 후보물질이다, HA는 주요인플루엔자 표면 당단백질이며, 인플루엔자에 대한 광범위한 방어력을 제공하는 중요한 표적으로 여겨지고 있으며, 현재 이용 가능한 백신 중 가장 중요한 표적으로 여겨지고 있습니다. 현재 사용 가능한 독감 백신의 주요 타깃으로 여겨지고 있습니다.
12월에는 4가 독감백신 mRNA-1010의 임상 1상 중간결과를 발표하며, 고령자 및 젊은 성인에서 최소 용량으로도 4가지 독감주 모두에 대한 역가 상승에 성공했으며, 안전성에 대한 심각한 우려는 없었다고 밝혔습니다. 안전성에 대한 우려는 없었다고 발표했습니다. 이는 계절성 독감, SARS-CoV-2 및 RSV의 순환 균주에 대한 범 호흡기 단일 용량 부스터 백신 개발을 위한 중요한 이정표가 될 것입니다.
주요 7개국의 mRNA-1010 시장에 대해 조사했으며, 시장의 개요와 2025-2032년 판매 예측 데이터, 경쟁 구도 및 국가별 동향 등을 제공하고 있습니다.
목차
제1장 리포트의 서론
제2장 계절성 인플루엔자에 대한 mRNA-1010의 개요
- 제품 상세
- 임상 개발
- 기타 개발 활동
- 제품 개요
제3장 경쟁 구도(출시 치료법)
제4장 경쟁 구도(후기 단계 신규 치료법)
제5장 mRNA-1010 시장 평가
- 계절성 인플루엔자에 대한 mRNA-1010의 시장 전망
- 주요 7개국 시장 분석
- 주요 7개국에서 계절성 인플루엔자에 대한 mRNA-1010의 시장 규모
- 국가별 시장 분석
제6장 SWOT 분석
제7장 애널리스트의 견해
제8장 부록
제9장 DelveInsight의 서비스 내용
제10장 면책사항
제11장 DelveInsight 소개
제12장 리포트 구입 옵션
KSA
“"mRNA-1010 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about mRNA-1010 for seasonal influenza in the seven major markets. A detailed picture of the mRNA-1010 for seasonal influenza in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the mRNA-1010 for seasonal influenza. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the mRNA-1010 market forecast analysis for seasonal influenza in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in seasonal influenza.
Drug Summary:
mRNA-1010 is Moderna's first seasonal influenza mRNA vaccine candidate to enter the clinic. The mRNA-1010 is a quadrivalent vaccine candidate that encodes for hemagglutinin glycoproteins of the four influenza strains recommended by the WHO for the prevention of influenza, including influenza A/H1N1, A/H3N2, and Influenza B/Yamagata- and B/Victoria-lineages. HA is a major influenza surface glycoprotein considered an important target to generate broad protection against influenza and is the primary target of currently available influenza vaccines.
In December, based on the positive interim results of the Phase I study of the quadrivalent flu vaccine, mRNA-1010, the company announced the successfully boosted titers against all four flu strains in older and younger adults, even at the lowest dose, with no significant safety concerns. These were important milestones toward developing an annual pan-respiratory single-dose booster vaccine adapted to the circulating strains of seasonal influenza, SARS-CoV-2, and RSV.
Scope of the Report:
The report provides insights into:
- A comprehensive product overview including the mRNA-1010 description, mechanism of action, dosage and administration, research and development activities in seasonal influenza.
- Elaborated details on mRNA-1010 regulatory milestones and other development activities have been provided in this report.
- The report also highlights the mRNA-1010 research and development activities in seasonal influenza across the United States, Europe and Japan.
- The report also covers the patents information with expiry timeline around mRNA-1010.
- The report contains forecasted sales of mRNA-1010 for seasonal influenza till 2032.
- Comprehensive coverage of the late-stage emerging therapies for seasonal influenza.
- The report also features the SWOT analysis with analyst views for mRNA-1010 in seasonal influenza.
Methodology:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
mRNA-1010 Analytical Perspective by DelveInsight
- In-depth mRNA-1010 Market Assessment
This report provides a detailed market assessment of mRNA-1010 for seasonal influenza in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.
- mRNA-1010 Clinical Assessment
The report provides the clinical trials information of mRNA-1010 for seasonal influenza covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights:
- In the coming years, the market scenario for seasonal influenza is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence mRNA-1010 dominance.
- Other emerging products for seasonal influenza are expected to give tough market competition to mRNA-1010 and launch of late-stage emerging therapies in the near future will significantly impact the market.
- A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of mRNA-1010 in seasonal influenza.
- Our in-depth analysis of the forecasted sales data of mRNA-1010 from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the mRNA-1010 in seasonal influenza.
Key Questions
- What is the product type, route of administration and mechanism of action of mRNA-1010?
- What is the clinical trial status of the study related to mRNA-1010 in seasonal influenza and study completion date?
- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the mRNA-1010 development?
- What are the key designations that have been granted to mRNA-1010 for seasonal influenza?
- What is the forecasted market scenario of mRNA-1010 for seasonal influenza?
- What are the forecasted sales of mRNA-1010 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
- What are the other emerging products available and how are these giving competition to mRNA-1010 for seasonal influenza?
- Which are the late-stage emerging therapies under development for the treatment of seasonal influenza?
Table of Contents
1. Report Introduction
2. mRNA-1010 Overview in seasonal influenza
- 2.1. Product Detail
- 2.2. Clinical Development
- 2.2.1. Clinical studies
- 2.2.2. Clinical trials information
- 2.2.3. Safety and efficacy
- 2.3. Other Developmental Activities
- 2.4. Product Profile
3. Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Therapies)
5. mRNA-1010 Market Assessment
- 5.1. Market Outlook of mRNA-1010 in seasonal influenza
- 5.2. 7MM Analysis
- 5.2.1. Market Size of mRNA-1010 in the 7MM for seasonal influenza
- 5.3. Country-wise Market Analysis
- 5.3.1. Market Size of mRNA-1010 in the United States for seasonal influenza
- 5.3.2. Market Size of mRNA-1010 in Germany for seasonal influenza
- 5.3.3. Market Size of mRNA-1010 in France for seasonal influenza
- 5.3.4. Market Size of mRNA-1010 in Italy for seasonal influenza
- 5.3.5. Market Size of mRNA-1010 in Spain for seasonal influenza
- 5.3.6. Market Size of mRNA-1010 in the United Kingdom for seasonal influenza
- 5.3.7. Market Size of mRNA-1010 in Japan for seasonal influenza
6. SWOT Analysis
7. Analysts' Views
8. Appendix
- 8.1. Bibliography
- 8.2. Report Methodology
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
12. Report Purchase Options
